Oenon Holdings,Inc. FY2026 Q2 Earnings Report

Quick View

Executive Summary

The trend of higher revenue and higher earnings continued, with growth in the high-margin Enzyme Pharmaceuticals Business driving an improvement in overall profitability. Revenue was ¥436.7B (+3.3% year on year), Operating Income was ¥25.6B (+10.4%), and Ordinary Income was ¥26.5B (+10.5%). Net Income attributable to owners of the parent was ¥19.7B (+6.2%; on a consolidated net income basis including net income attributable to non-controlling interests, ¥19.8B, +6.8%), with both measures exceeding the same period of the previous year. The Operating Income margin improved to 5.9% (5.5% in the previous year), and the high growth and high margins of the Enzyme Pharmaceuticals Business supported higher earnings while the core Alcoholic Beverages Business (91.6% of revenue) remained sluggish.

Factors Affecting Financial Performance

【Revenue】Revenue increased 3.3% year on year to ¥436.7B. By segment, the core Alcoholic Beverages Business generated ¥400.0B (91.6% of the total, YoY +2.4%), the Enzyme Pharmaceuticals Business generated ¥29.7B (6.8%, YoY +17.8%), and the Real Estate Business generated ¥6.7B (1.5%, YoY +0.8%). Although growth in the Alcoholic Beverages Business was moderate, strong growth in the Enzyme Pharmaceuticals Business was the primary driver of the increase in company-wide revenue.

【Profit and Loss】Operating Income was ¥25.6B (YoY +10.4%), while Ordinary Income was ¥26.5B (YoY +10.5%), with the earnings growth rate exceeding the revenue growth rate. Operating Income from the Enzyme Pharmaceuticals Business surged to ¥9.4B (YoY +64.8%, margin 31.6%), offsetting the decline in the Alcoholic Beverages Business, which generated ¥12.2B (YoY -9.8%, margin 3.0%), and raising the company-wide profit margin. The Real Estate Business maintained its high margin, generating ¥3.96B (YoY +1.8%, margin 59.5%) and providing support to earnings. The impact of non-operating and extraordinary gains and losses was limited, and the gap between Ordinary Income and Net Income remained within the scope of the effective tax burden of 26.9%. Overall, the Company delivered higher revenue and higher earnings for the period.

Segment Analysis

Of Operating Income of ¥25.6B, the Alcoholic Beverages Business accounted for ¥12.2B (48% contribution), the Enzyme Pharmaceuticals Business for ¥9.4B (37%), and the Real Estate Business for ¥3.96B (15%). The Alcoholic Beverages Business has a large 91.6% share of revenue but low profitability, with a 3.0% margin, and Operating Income declined 9.8% YoY. In contrast, although the Enzyme Pharmaceuticals Business accounted for only 6.8% of revenue, it achieved a high 31.6% margin and 64.8% YoY earnings growth, making it the primary driver of company-wide earnings growth. The Real Estate Business is small, accounting for 1.5% of revenue, but has an exceptionally high 59.5% margin and functions as a stable source of earnings. Growth in the two non-alcoholic beverage segments offset the decline in the core business and resulted in higher company-wide earnings.

Key Financial Indicators

【Profitability】The Operating Income margin improved to 5.9% (5.5% in the previous year), the gross margin improved to 18.7% (18.3% in the previous year), and the Net Income margin on an attributable-to-owners-of-the-parent basis improved to 4.5% (4.4% in the previous year). 【Cash Flow Quality】Operating Cash Flow (OCF) was limited to ¥0.3B, and the OCF/Net Income ratio was approximately 0.02x against Net Income attributable to owners of the parent of ¥19.7B, indicating a low level. An increase in inventories (-¥18.3B) and a decrease in trade payables (-¥9.8B) placed pressure on working capital, delaying the conversion of earnings into cash. 【Investment Efficiency】ROE was 7.0%, comprising a revenue-to-total-assets ratio of 0.78x (for the half-year period, before annualization) and financial leverage of 1.98x. 【Financial Soundness】The Equity Ratio was 50.6%, the current ratio was 119.3%, and the quick ratio was 79.9%. While short-term borrowings increased 128.2% YoY to ¥44.5B, long-term borrowings declined to ¥3.0B. Short-term borrowings accounted for approximately 94% of interest-bearing debt, and cash and deposits/short-term borrowings stood at 0.19x, indicating limited liquidity headroom.

Cash Flow Analysis

Operating Cash Flow was ¥0.3B, an improvement from -¥3.8B in the previous year, but it remained low relative to the earnings level. The collection of trade receivables generated a positive effect of ¥50.4B, while inventory accumulation had a negative impact of ¥18.3B and the decrease in trade payables had a negative impact of ¥9.8B. The increase in working capital constrained OCF. Investing Cash Flow was -¥11.1B, mainly due to the acquisition of property, plant and equipment, while Financing Cash Flow was +¥10.2B, as a net increase in short-term borrowings (+¥25.0B) secured funds exceeding dividend payments (-¥6.3B) and share repurchases (-¥3.2B). As a result, Free Cash Flow (Operating Cash Flow + Investing Cash Flow) was -¥10.7B, indicating that capital expenditures and shareholder returns were not fully funded by operating activities and were supplemented by increased short-term borrowings.

Earnings Quality

Non-operating income was ¥2.1B (0.5% of revenue), a small amount primarily comprising structurally stable items such as dividend income of ¥0.6B and equity in earnings of affiliates of ¥0.5B. Extraordinary income was ¥0.9B (gain on sale of fixed assets of ¥0.7B and gain on sale of investment securities of ¥0.2B), while extraordinary losses were ¥0.3B (loss on disposal and sale of fixed assets), resulting in a net gain of only +¥0.6B and having a limited impact on profit before tax of ¥27.1B. The gap among Ordinary Income of ¥26.5B, profit before tax of ¥27.1B, and Net Income attributable to owners of the parent of ¥19.7B was attributable to the income tax burden at an effective tax rate of 26.9%. Distortions from temporary factors were limited, and earnings quality was generally recurring. However, OCF remained at approximately 0.02x Net Income attributable to owners of the parent, and the deterioration in working capital centered on inventory growth created a gap between accounting earnings and cash flow. This point requires monitoring from the perspective of earnings cash conversion.

Earnings Forecast and Guidance

Progress against the full-year plan was 49.1% for revenue (436.7/890.0B), 64.7% for Operating Income (25.6/39.5B), 66.3% for Ordinary Income (26.5/40.0B), and 67.9% for Net Income attributable to owners of the parent (19.7/29.0B), with all exceeding the 50% benchmark for a half-year period. The Company has left both its full-year earnings forecast and dividend forecast unchanged, with no revisions made. The full-year plan assumes year-on-year declines in both Operating Income and Ordinary Income (-4.5% and -6.8%, respectively), suggesting that, in contrast with the strong first-half progress, the plan may incorporate changes in the external environment and inventory adjustment costs in the second half.

Shareholder Returns

The full-year dividend forecast is ¥12 per share, implying a Payout Ratio of approximately 23.3% against forecast EPS of ¥51.47. Dividend payments during the first half amounted to ¥6.3B, and the Company repurchased ¥3.2B of its own shares, resulting in total shareholder returns of ¥9.4B. First-half Free Cash Flow was -¥10.7B, indicating that shareholder returns were not fully funded by operating activities and were supplemented by short-term borrowings. However, the Payout Ratio itself remains low, supporting dividend sustainability. No revision has been made to the dividend forecast, and the continuation of the current policy is expected.

Risk Factors

1. Concentration of revenue in the core business: The Alcoholic Beverages segment accounts for 91.6% of revenue, while its Operating Income margin of 3.0% is below the company-wide average of 5.9%. This structure makes company-wide performance susceptible to fluctuations in alcoholic beverage demand and the impact of price competition.

2. Deterioration in working capital and lower cash conversion: Operating Cash Flow was ¥0.3B, or approximately 0.02x Net Income attributable to owners of the parent of ¥19.7B. Inventories increased from the previous year (CF impact of -¥18.3B), while trade payables also declined (-¥9.8B), making trends in inventory and accounts payable management an ongoing area of focus.

3. Dependence on short-term funding: Short-term borrowings were ¥44.5B, up 128.2% from the previous year, while long-term borrowings declined to ¥3.0B. Short-term borrowings accounted for approximately 94% of interest-bearing debt. Cash and deposits were ¥8.3B, or only 0.19x short-term borrowings, and the quick ratio was also 79.9%, indicating changes in the short-term funding position.

Industry Benchmark (Reference; Compiled by the Company)

Profitability and Returns

Median data is required for a relative comparison of profitability levels within the food and beverage industry; at present, only the Company’s own figures can be confirmed.

Growth and Capital Efficiency

An assessment of the Company’s positioning relative to the industry median will also be possible once comparison data for the growth rate is available.

※Source: Compiled by the Company

Key Points from the Earnings Results

1. The Company is transitioning toward an earnings structure in which the Enzyme Pharmaceuticals Business generates 37% of Operating Income despite accounting for only 6.8% of revenue. Expansion of the high-margin segment is serving as a structural driver of the improvement in the company-wide profit margin.

2. Progress against the full-year plan was 64.7% for Operating Income and 67.9% for Net Income attributable to owners of the parent, substantially exceeding the 50% half-year benchmark. The first-half earnings growth pace is therefore ahead of the Company’s plan.

3. Meanwhile, Operating Cash Flow was ¥0.3B, or only 0.02x Net Income attributable to owners of the parent. The deterioration in working capital resulting from increased inventories and decreased trade payables is constraining the conversion of earnings into cash, making this a key point in the earnings data.

Theoretical Share Price (Reference Value)

This is a mechanically calculated reference range based solely on publicly disclosed data using a residual income model (Ohlson-type model with an explicit 5-year fade). It is not a forecast of the market share price or a recommendation to take any specific investment action.

Sensitivity: ¥513–¥543 at cost of equity ±1%; ¥527–¥528 at ω±0.1.

Notes:

• Because progress in Net Income against the full-year forecast (68%) exceeds the standard benchmark (50%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies progressing ahead of plan tend to exceed forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Net assets as of the end of the quarter are used (there is a timing gap relative to the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: residual income model / interest rate reference month: 2026-07 / this value does not forecast or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, with consultation with a professional advisor as necessary.

---End of Report---